Pfizer Moves to Dismiss Lawsuit From COVID-19 Vaccine Trial, Citing ‘Prototype’ Agreement

Albert Bourla, chief executive officer of Pfizer pharmaceutical company, at the New York Stock Exchange in New York on Jan. 17, 2019. (Drew Angerer/Getty Images)

Albert Bourla, chief executive officer of Pfizer pharmaceutical company, at the New York Stock Exchange in New York on Jan. 17, 2019. (Drew Angerer/Getty Images)

US NEWS

Pfizer Moves to Dismiss Lawsuit From COVID-19 Vaccine Trial, Citing ‘Prototype’ Agreement

By Zachary Stieber

May 21, 2022 Updated: May 21, 2022

biggersmaller 

Print

Pfizer has asked a U.S. court to throw out a lawsuit from a whistleblower who revealed problems at sites that tested Pfizer’s COVID-19 vaccine. Brook Jackson, the whistleblower, alleged in a suit that was unsealed in February that Pfizer and associated parties violated clinical trial regulations and federal laws, including the False Claims Act. In its motion to dismiss, Pfizer says the regulations don’t apply to its vaccine contract with the U.S. Department of Defense because the agreement was executed under the department’s Other Transaction Authority (OTA), which gives contract holders the ability to skirt many rules and laws that typically apply to contracts.”

Pfizer Moves to Dismiss Lawsuit From COVID-19 Vaccine Trial, Citing ‘Prototype’ Agreement (theepochtimes.com)

Published by markskidmore

Mark Skidmore is Professor of Economics at Michigan State University where he holds the Morris Chair in State and Local Government Finance and Policy. His research focuses on topics in public finance, regional economics, and the economics of natural disasters. Mark created the Lighthouse Economics website and blog to share economic research and information relevant for navigating tumultuous times.

Leave a Reply

%d bloggers like this: